Attenuation of hypertension by insulin-sensitizing agents

Hypertension

Volumn 28, Issue 2, 1996, Pages 219-223

  Kotchen, Theodore A ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

hyperinsulinism; insulin; insulin resistance

Indexed keywords

BENFLUOREX; CLOFIBRATE; ETOMOXIR; METFORMIN; MEVINOLIN; THIAZOLIDINE DERIVATIVE; VANADIUM;

ANTIHYPERTENSIVE THERAPY; DRUG EFFECT; HUMAN; HYPERTENSION; INSULIN METABOLISM; INSULIN RELEASE; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

EID: 0029746269     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.28.2.219     Document Type: Review

References (79)

1. O'Shaughnessy IM, Kotchen TA. Epidemiologic, physiologic, and clinical implications of hypertension and insulin resistance. Curr Opin Cardiol. 1993;8:757-764.
2. Lind L, Berne C, Lithell H. Prevalence of insulin resistance in essential hypertension. J Hypertens. 1995;13:1457-1462.
3. Sharma AM, Schorr U, Distler A. Insulin resistance in young salt-sensitive normotensive subjects. Hypertension. 1993;21: 270-273.
4. Bigazzi R, Bianchi S, Baldari G, Campese VM. Clustering of cardiovascular risk factors in salt-sensitive patients with essential hypertension: role of insulin. Am J Hypertens. 1996;9:24-32.
5. Zavaroni I, Coruzzi P, Bonini L, Luigi G, Mossini L, Musiari L, Gasparini P, Fantuzzi M, Reaven GM. Association between salt sensitivity and insulin concentrations in patients with hypertension. Am J Hypertens. 1995;8:855-858.
6. Kotchen TA, Zhang HY, Covelli M, Blehschmidt N. Insulin resistance and blood pressure in Dahl rats and in one-kidney, one-clip hypertensive rats. Am J Physiol. 1991;261:E692-E697.
7. Buchanan TA, Siopos GF, Madrilejo N, Liu C, Campese VM. Hypertension without peripheral insulin resistance in spontaneously hypertensive rats. Am J Physiol. 1992;262:E14-E19.
8. Anderson EA, Mark AL. The vasodilator action of insulin: implications for the insulin hypothesis of hypertension. Hypertension. 1993; 21:136-141.
9. Sawicki PT, Heinemann L, Starke A, Berger M. Hyperinsulinaemia is not linked with blood pressure elevation in patients with insulinoma. Diabetologia. 1992;35:649-652.
10. American Heart Association. Nonpharmacological approaches to the control of high blood pressure. Hypertension. 1986;8:444-467.
11. Rocchini AP, Key J, Bondie D, Chico R, Moorhead C, Katch V, Martin R. The effect of weight loss on the sensitivity of blood pressure to sodium in obese adolescents. N Engl J Med. 1989; 231:580-585.
12. Su H-Y, Sheu WH, Chin HML, Jeng CY, Chen YDI, Reaven GM. Effect of weight loss on blood pressure and insulin resistance in normotensive and hypertensive obese individuals. Am J Hypertens. 1995;8:1067-1071.
13. Reaven GM, Ho H, Hoffman BB. Somatostatin inhibition of fructose induced hypertension. Hypertension. 1989;14:117-120.
14. Carretta R, Fabris B, Fischetti F, Constantini M, DeBiasi F, Muiesan S, Bardelli M, Vran F, Campanacci L. Reduction of blood pressure in obese hyperinsulinaemic hypertensive patients during somatostatin infusion. J Hypertens. 1989;7(suppl 6):S196-S197.
15. Landin K, Holm G, Tengborn L, Smith U. Guargum improves insulin sensitivity, blood lipids, blood pressure, and fibrinolysis in healthy men. Am J Clin Nutr. 1992;56:1061-1065.
16. Dubey RK, Zhang HY, Reddy SR, Boegehold MA, Kotchen TA. Pioglitazone attenuates hypertension and inhibits growth of renal arteriolar smooth muscle in rats. Am J Physiol. 1993;265:R726-R732.
17. Yoshioka S, Nishino H, Shiraki T, Ikeda K, Koike H, Okuno A, Wada M, Fujiwara T, Hosikoshi H. Antihypertensive effects of CS-045 treatment in obese Zucker rats. Metabolism. 1993;42:75-80.
18. Kaufman LN, Peterson MM, DeGrange LM. Pioglitazone prevents diet induced hypertension in rats. Diabetes. 1993;42:47A. Abstract.
19. Meehan WP, Buchanan TA, Hseuh W. Effects of pioglitazone treatment in fructose-fed rats. Hypertension. 1993;22:452. Abstract.
20. Lee MK. The effect of CS-045 to prevent insulin resistance and hypertension in high fructose fed rats. In: Abstracts of the 75th Annual Meeting of the Endocrine Society; June 9-12, 1993; Las Vegas, Nevada; p 493.
21. Lardinois CK, Grinsell J, Michaels JR. Pioglitazone attenuates basal and postprandial insulin concentrations and decreases blood pressure in spontaneously hypertensive rats. Am J Hypertens. 1994;7:53A. Abstract.
22. Morgan DA, Mark AL. Ciglitazone lowers arterial pressure independent of increased insulin sensitivity in spontaneously hypertensive rats. Am J Hypertens. 1993;6:2A. Abstract.
23. Pershadsingh HA, Szollosi J, Benson S, Hyun WC, Feuerstein BG, Kurtz TW. Effect of ciglitazone on blood pressure and intracellular calcium metabolism. Hypertension. 1993;21:1020-1023.
24. Kemnitz JW, Elson DF, Roecker EB, Baum ST, Bergman RN, Mejlasson MD. Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin, and lipid levels, and lowers blood pressure in obese, insulin-resistant rhesus monkeys. Diabetes. 1994;43:204-211.
25. Ogihara T, Rakugi H, Ikegami H, Mikami H, Masuo K. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens. 1995;8:316-320.
26. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med. 1994;331:1188-1193.
27. Morgan DA, Ray CA, Balon TW, Mark AL. Metformin increases insulin sensitivity and lowers arterial pressure in spontaneously hypertensive rats. Clin Res. 1992;40:740A. Abstract.
28. Verma S, Bhanot S, McNeill JH. Metformin decreases plasma insulin levels and systolic blood pressure in spontaneously hypertensive rats. Am J Physiol. 1994;267:H1250-H1253.
29. Landin K, Tengborn L, Smith U. Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors. J Intern Med. 1991;229:181-187.
30. Giugliano D, DeRosa N, DiMario G, Marfella R, Acampora R, Buoninconti R, D'Onofrio F. Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive obese women. Diabetes Care. 1993;16:1387-1390.
31. Giugliano D, Quatraro A, Consol G, Minei A, Ceriello A, DeRosa N. Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors. Eur J Clin Pharmacol. 1993;44:107-112.
32. Chan JCN, Tomilson B, Critchley JA, Cockran CS, Walden RJ. Metabolic and hemodynamic effects of metformin and glibenclamide in normotensive NIDDM patients. Diabetes Care. 1993;16:1035-1038.
33. Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism. 1994; 43:647-654.
34. Dorella M, Datos V, Campagnolo M, Giusto M, Ceolotto B, Palatini P, Semplicini A, DelPrato S. Metformin treatment in non-diabetic hypertensive patients. Diabetes. 1993;42:58A. Abstract.
35. Ngai DK, Yudkin JS. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. Diabetes Care. 1993;16:621-629.
36. Bhanot S, McNeill JH. Vanadyl sulfate lowers plasma insulin and blood pressure in spontaneously hypertensive rats. Hypertension. 1994;24:625-632.
37. Bhanot S, Bryer-Ash M, Cheung A, McNeill JH. Bis(maltolato)oxovanadium(IV), attenuates hyperinsulinemia and hypertension in spontaneously hypertensive rats. Diabetes. 1994;43: 857-861.
38. Swislocki A, Eason T. Glucose tolerance and blood pressure are improved in the spontaneously hypertensive rat by ethyl-2-(6-(4-chlorophenoxy)-hexyl)oxirane-2-carboxylate (etomoxir), an inhibitor of fatty acid oxidation. Am J Hypertens. 1994;7:739-744.
39. Roman RJ, Ma Y-H, Frohlich B, Markham B. Clofibrate prevents the development of hypertension in Dahl salt-sensitive rats. Hypertension. 1993;21:985-988.
40. Storlien LH, Oakes ND, Pan DA, Kusunoki M, Jenkins AB. Syndromes of insulin resistance in the rat: inducement by diet and amelioration with benfluorex. Diabetes. 1993;42:457-462.
41. Nestler JE, Beer NA, Jakubowicz DA, Colombo C, Beer RM. Effects of insulin reduction with benfluorex on serum DHEA, DHEA sulfate, and blood pressure in middle-aged and elderly men. J Clin Endocrinol Metab. 1995;80:700-706.
42. Donnell MP, Kasiske BL, Katz SA, Schmitz PG, Keane WF. Lovastatin but not enalapril reduces glomerular injury in Dahl salt-sensitive rats. Hypertension. 1992;20:651-658.
43. Hofmann CA, Colca JR. New oral thiazolidinedione antidiabetic agents act as insulin sensitizers. Diabetes Care. 1992;12:1075-1078.
44. Katayama S, Abe M, Kashiwabara H, Kosegawa I, Ishii J. Evidence against a role of insulin in hypertension in spontaneously hypertensive rats: CS-045 does not lower blood pressure despite improvement of insulin resistance. Hypertension. 1994;23(part 2):1071-1074.
45. Zhang HY, Reddy SR, Kotchen TA. Antihypertensive effect of pioglitazone is not invariably associated with increased insulin sensitivity. Hypertension. 1994;24:106-110.
46. Bailey C, Turner RC. Metformin: review article. N Engl J Med. 1996;334:574-579.
47. Elkeles RS, Heding LG, Palsey RB. The long-term effects of chlorpropamide on insulin, C-peptide and proinsulin secretion. Diabetes Care. 1982;5:427-429.
48. Smith RJ. Effects of the sulfonylureas on muscle glucose homeostasis. Am J Med. 1990;89(suppl 2A):38S-44S.
49. Ballagi-Pordany G, Koltai MZ, Aranyl Z, Pogatsa G. Direct effect of hypoglycemic sulphonylureas on the cardiovascular system of dogs. Diabetes Res Clin Pract. 1991;11:47-52.
50. Peuler JD, Johnson BAB, Phare SM, Sowers J. Sex-specific effects of an insulin secretagogue. Hypertension. 1993;22:214-220.
51. Morgan DA, Mark AL. Contrasting effects of a biguanide and a sulfonylurea on arterial pressure in spontaneously hypertensive rats. Hypertension. 1993;22:452. Abstract.
52. Levy J, Vandenberg M, Grunberger G. Insulin versus glipizide treatment in patients with non-insulin-dependent diabetes mellitus: effects on blood pressure and glucose tolerance. Am J Hypertens. 1995; 8:445-453.
53. Lardinois CK, Sare JS, Michaels JR, Gonzalez R, Starich GH. Acarbose attenuates basal and postprandial insulin levels but fails to lower blood pressure in spontaneously hypertensive rats. Am J Hypertens. 1994;7:53A. Abstract.
54. Roullet RJ, Xue H, Papu AJ, Roullet C, Holcomb S, McCarron DA. Mevalonate availability and cardiovascular functions. Proc Natl Acad Sci USA. 1993;90:11728-11732.
55. Law RE, Xi XP, Hseuh WA. Troglitazone inhibits insulin, EGF, and PDGF mitogenic signal transduction in A10 vascular smooth muscle and mesangial cells. Hypertension. 1995;26:553. Abstract.
56. Donnell MP, Kasiske BL, Kim Y, Alturn D, Keane WF. Lovastatin inhibits proliferation of rat mesangial cells. J Clin Invest. 1993;91:83-87.
57. Bunting CE, Koschinsky T, Rutter R, Gries FA. Metformin inhibits the growth of human vascular cells: a new potentially antiatherogenic drug effect. Diabetologia. 1986;29:523A. Abstract.
58. Peuler JD, Phare SM, Iannucci AR, Hodorek MJ. Differential inhibitory effects of antidiabetic drugs on arterial smooth muscle cell proliferation. Am J Hypertens. 1996;9:188-192.
59. Andrews HE, Brackdorfer KR, Dunn RC, Jacobs M. Low density lipoproteins inhibit endothelium-dependent relaxation in rabbit aorta. Nature. 1987;327:237-239.
60. Creager MA, Cooke JP, Mendelsohn ME, Gallagher SJ, Coleman SM, Loscalzo J, Dzau V. Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J Clin Invest. 1990;86:228-234.
61. Laakso M, Edelman SV, Brechtel G, Baron AD. Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man: a novel mechanism for insulin resistance. J Clin Invest. 1990;85:1844-1852.
62. Soltis EE, Katovich MJ. Reduction in aortic smooth muscle beta-adrenergic responsiveness results in enhanced norepinephrine responsiveness in the Dahl salt-sensitive rat. Clin Exp Hypertens A. 1991;13:117-132.
63. Chowienczyk PJ, Watts GF, Cockcroft JR, Ritter JM. Impaired endothelium-dependent vasodilation of forearm resistance vessels in hypercholesterolaemia. Lancet. 1992;340:1430-1432.
64. Sorensen KE, Celermajer DS, Georgakopoulos D, Hatcher G, Betteridge DJ, Deanfield JE. Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein (a) level. J Clin Invest. 1994;93:50-55.
65. Standley PR, Rose KA, Sowers JR. Increased basal arterial smooth muscle glucose transport in the Zucker rat. Am J Hypertens. 1995; 8:48-52.
66. Vollenweider P, Randin D, Tappy L, Jequier E, Nicold P, Scherrer U. Impaired insulin-induced sympathetic neural activation and vasodilation in skeletal muscle in obese humans. J Clin Invest. 1994; 93:2365-2371.
67. Zanchi A, Delacretaz E, Taleb V, Gaillard R, Jeanrenaud B, Brunner HR, Waeber B. Endothelial function of the mesenteric arteriole and mechanical behavior of the carotid artery in rats with insulin resistance and hypercholesterolemia. J Hypertens. 1995;13:1463-1470.
68. Kotchen TA, Zhang HY, Reddy SR, Hoffman RG. Effect of pioglitazone on vascular reactivity in vivo and in vitro. Am J Physiol. 1996;270:R660-R666.
69. Bourghli M, Sowers JR, Peuler JD. Direct and insulin-related attenuating effects of pioglitazone on aortic vascular contractility. Am J Hypertens. 1994;7:71A. Abstract.
70. Draznin B, Sussman KE, Eckel RH, Kao M, Yost T, Sherman NA. Possible role of cytosolic free calcium concentrations in mediating insulin resistance of obesity and hyperinsulinemia. J Clin Invest. 1988;82:1848-1852.
71. Postnov YV, Orlov SN. Ion transport across plasma membranes in primary hypertension. Physiol Rev. 1985;65:904-945.
72. Balla RC, Toth KF, Tan E, Mathias E, Sharma RV. Vascular effects of metformin: possible mechanisms for its antihypertensive action in spontaneously hypertensive rats. Am J Hypertens. In press.
73. Zhang F, Sowers JR, Ram JL, Standley PR, Peuler JD. Effects of pioglitazone in calcium channels in vascular smooth muscle. Hypertension. 1994;24:170-175.
74. Buchanan TA, Meehan WP, Jeng YY, Yang D, Chan TM, Nadler JL, Scott S, Rude RK, Hseuh WA. Blood pressure lowering by pioglitazone: evidence for a direct vascular effect. J Clin Invest. 1995; 96:354-360.
75. Brands MW, Hopkins TE. Poor glycemic control induces hypertension in diabetes mellitus. Hypertension. 1996;27(part 2): 735-739.
76. Ting HH, Timimi FK, Boles KS, Creager SJ, Ganz P, Creager MA. Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. J Clin Invest. 1996; 97:22-28.
77. Williams B. Glucose-induced vascular smooth muscle dysfunction: the role of protein kinase C. J Hypertens. 1995;13:477-486.
78. Lithell HDL. Effects of antihypertensive agents on insulin, glucose, and lipid metabolism. Diabetes Care. 1991;14:203-209.
79. Navarro-Cid J, Maeso R, Perez-Vizcaino F, Cachofeiro V, Ruilope LM, Tamargo J, Lahera V. Effects of losartan on blood pressure, metabolic alterations, and vascular reactivity in the fructose-induced hypertensive rat. Hypertension. 1995;26(part 2):1074-1078.